IGFN1

IGFN1 is a multi-domain skeletal muscle protein that localizes to the Z-disc and functions as a critical regulator of actin dynamics during myoblast fusion and differentiation. Its three N-terminal globular domains mediate Z-disc targeting, where it forms a complex with KY and filamin C (FLNC) and interacts with the actin nucleating protein COBL, stabilizing COBL and inhibiting its actin-ruffling activity to control the G:F actin ratio required for proper myotube formation (PMID:20206623, PMID:32768501). Loss of IGFN1 completely blocks myoblast fusion without abolishing differentiation marker expression, and re-expression of the IGFN1_v1 isoform partially rescues fusion defects (PMID:28665998). IGFN1 also binds eukaryotic translation elongation factor eEF1A and is markedly upregulated upon muscle denervation, linking it to translational regulation under atrophic conditions (PMID:18756455).

1. 2008 Medium

   Establishing that IGFN1 is a skeletal-muscle-specific protein that physically engages the translational machinery answered the question of what molecular partners this uncharacterized multi-domain protein interacts with, implicating it in regulation of protein synthesis during muscle atrophy.

   Evidence Yeast two-hybrid screen of human skeletal muscle cDNA library with in vitro binding validation; denervation expression profiling

   PMID:18756455

   Open questions at the time

   • Interaction with eEF1A confirmed only by Y2H and in vitro binding without in vivo validation
   • Functional consequence on translation not directly measured
   • Whether upregulation during denervation is causally linked to atrophy remains untested
2. 2010 High

   Determining that IGFN1 localizes to the Z-disc through its N-terminal domains and forms a ternary complex with KY and FLNC established its role as a sarcomeric scaffolding protein rather than a diffuse cytoplasmic factor.

   Evidence Yeast two-hybrid, co-immunoprecipitation, and immunofluorescence in C2C12 myotubes and neonatal cardiomyocytes; domain-deletion constructs

   PMID:20206623

   Open questions at the time

   • Stoichiometry and architecture of the KY–IGFN1–FLNC complex are unknown
   • Whether the complex is required for Z-disc integrity or is regulatory has not been tested
3. 2017 High

   Demonstrating that IGFN1 loss blocks myoblast fusion while preserving differentiation marker expression resolved whether the protein is needed for general differentiation or specifically for the cell fusion step of myogenesis.

   Evidence shRNA knockdown and CRISPR/Cas9 exon 13 deletion in C2C12 cells with rescue by IGFN1_v1 overexpression

   PMID:28665998

   Open questions at the time

   • In vivo validation in animal models is absent
   • Which IGFN1 domain(s) are critical for the fusion function has not been mapped
4. 2018 Medium

   Identifying a stable intronic G-quadruplex that regulates IGFN1 alternative splicing revealed a cis-regulatory mechanism controlling isoform diversity, though the physiological relevance in muscle was tested only in a renal carcinoma cell line.

   Evidence Biophysical assays (CD, gel shift, RT/PCR stop assays) and pyridostatin treatment of UOK146 cells

   PMID:30335789

   Open questions at the time

   • Splicing regulation by the G-quadruplex has not been confirmed in skeletal muscle cells
   • Which IGFN1 isoforms are functionally distinct remains unresolved
5. 2020 High

   Showing that IGFN1 binds and inhibits the actin nucleator COBL at the Z-disc, with IGFN1 loss causing elevated G:F actin ratios, provided a mechanistic explanation for how IGFN1 controls actin remodeling during myoblast fusion.

   Evidence Co-IP, proteomics pull-downs from skeletal muscle, G:F actin ratio measurements in IGFN1-deficient C2C12 cells, COS7 overexpression assay

   PMID:32768501

   Open questions at the time

   • Direct binding domains between IGFN1 and COBL have not been mapped
   • Whether COBL re-expression rescues fusion in IGFN1-null cells is untested
   • Proteasome interactions identified by proteomics have not been functionally explored

• It remains unknown whether IGFN1 functions in vivo as a required fusion factor, how its interactions with eEF1A and COBL are coordinated, and whether its isoforms have distinct sarcomeric functions.
• No in vivo knockout or disease-associated mutation data exist
• Relationship between eEF1A binding and COBL inhibition is unexplored
• No structural information on any IGFN1 domain or complex is available